Background
The Consolidated Standards of Reporting Trials (CONSORT) guidelines were developed in the mid-1990s for the explicit purpose of improving clinical trial reporting. However, there is little information regarding the adherence to CONSORT guidelines of recent publications of randomized controlled trials (RCTs) in oncology.
Methods
All phase III RCTs published between 2005 and 2009 were reviewed using an 18-point overall quality score for reporting based on the 2001 CONSORT statement. Multivariable linear regression was used to identify features associated with improved reporting quality. To provide baseline data for future evaluations of reporting quality, RCTs were also assessed according to the 2010 revised CONSORT statement. All statistical tests were twosided.
Results
A total of 357 RCTs were reviewed. The mean 2001 overall quality score was 13.4 on a scale of 0-18, whereas the mean 2010 overall quality score was 19.3 on a scale of 0-27. The overall RCT reporting quality score improved by 0.21 points per year from 2005 to 2009. Poorly reported items included method used to generate the random allocation (adequately reported in 29% of trials), whether and how blinding was applied (41%), method of allocation concealment (51%), and participant flow (59%). High impact factor (IF, P = .003), recent publication date (P = .008), and geographic origin of RCTs (P = .003) were independent factors statistically significantly associated with higher reporting quality in a multivariable regression model. Sample size, tumor type, and positivity of trial results were not associated with higher reporting quality, whereas funding source and treatment type had a borderline statistically significant impact.
Conclusion
The results show that numerous items remained unreported for many trials. Thus, given the potential impact of poorly reported trials, oncology journals should require even stricter adherence to the CONSORT guidelines.
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Randomized controlled trials (RCTs) are the gold standard for evaluating new therapies or strategies in medicine (1) . However, the results of poorly designed or poorly reported RCTs can have widespread detrimental consequences for routine clinical practice and may impair the quality of pooled analyses such as meta-analyses (2, 3) . Therefore, the Consolidated Standards of Reporting Trials (CONSORT) statement was developed by trial methodologists and editors of biomedical journals in the mid-1990s for the explicit purpose of improving clinical trial reporting (4) . The CONSORT statement, which provides guidance to authors regarding essential items that should be included in RCT reports, was updated in 2001 (and again in 2010) to incorporate new elements (5, 6) . Since its original publication in 1996, CONSORT has been supported by more than 400 journals (www.consort-statement.org) and editorial groups, including the International Committee of Medical Journal Editors (7) . As a result, the overall quality of RCT reporting has improved (8-11).
There is little information regarding the adherence of oncology trials to the CONSORT guidelines. Although RCT reporting quality has previously been assessed in rare tumor subtypes (8, 10, 12) , it has never been systematically and comprehensively investigated in all tumor types. Therefore, the primary objective of this study was to assess the overall reporting quality of oncology RCTs published between 2005 and 2009 according to the 2001 CONSORT statement. In addition, we investigated manuscript characteristics associated with better reporting quality. To provide baseline data for future evaluations of reporting quality, each RCT was also assessed with the more recent 2010 CONSORT guidelines.
Rating of Overall Reporting Quality
Based on the methodology used in previous studies (8, 10, 12, 14) , an overall quality score (OQS) was developed. The OQS consisted of 18 of the 22 items detailed in the 2001 CONSORT statement (Table 1) . Each item was scored 1 if it was well reported or 0 if it was not clearly reported or not stated; each item was weighted with equal importance. Concurrently, each RCT was also assessed using a 27-item OQS based on the more recent 2010 CONSORT guidelines (Table  2 ). Items 20 through 22, which assess the discussion section of RCTs, were excluded from the OQS because it was too difficult to objectively evaluate them during the primary analysis. Nevertheless, some data related to items 20-22 guidelines were collected to secondarily evaluate their association with the overall quality of reporting. Item 10 from the 2001 and 2010 guidelines, which assesses the separation of the generator and executor of the allocation sequence, was not evaluated separately but was included in the assessment of allocation concealment (Item 9, Tables 1 and 2 ). Although authors in other studies of reporting adequacy have singled out certain items for special emphasis as "Key Methodologic Factors" including item 9 (allocation concealment), item 11 (blinding), and item 16 (intentto-treat, ITT) (8, 10, 14) , the rationale was not clearly justified. The three items were included in the overall OQS in our analysis.
The rating methodology of each item was discussed among three authors (JP, DM, and BY) based on explanation and elaboration of the 2001 CONSORT statement (5) . The data from the first 20 trials (360 items) were independently rated by two investigators (JP and DM) who were blinded to each other's results. Among these 360 items, 37 discrepancies were identified; however, all were successfully resolved by consensus [23 items in favor of the principal extractor (JP) and 14 against]. The error rate of the principal data extractor was therefore 3.9% (14/360). Based on this finding, an updated data extraction form was then used by the primary extractor (JP) to capture the remaining data in this study.
Although most items in the OQS of the 2001 CONSORT guidelines (Table 1) were unambiguous, a few items were open to interpretation. To avoid any ambiguity, the following definitions were used for the purposes of this review. Allocation concealment is the method of masking upcoming treatment assignments from individuals involved in patient enrollment. Allocation concealment was considered adequately reported if there was a description of central randomization (eg, numbered or coded vehicles, opaque sealed envelopes, or sequentially numbered envelopes). These criteria were similar to both criteria recommended for Cochrane reviews and criteria used in previous reports (15) . ITT was considered adequately reported if the method was described, regardless of the actual definition of ITT used. Finally, blinding was considered adequately reported if the trial was clearly stated as an open trial or if the blinded population was clearly described (patients, physicians, and/or those assessing the outcomes) and if the similarities in the characteristics of true and sham interventions were stated (such as appearance, taste, smell, and method of administration).
Definition of Trial Characteristics
A "positive" trial was defined as one in which the experimental arm was deemed by trial investigators to be superior to the standard arm in superiority trials, not inferior in noninferiority trials, or equivalent in equivalence trials. A "negative" study was defined as one in which the experimental arm was deemed not superior, inferior, or not equivalent to the reference arm. All others were defined as "unclear." Trials were considered industry-funded if there was at least partial funding by an industry identified in the publication. The geographic regions where RCTs were led were derived from the addresses of the first author institutions. Cochran-Armitage tests for trend were used to identify a measurable change in reporting frequency of a single item over the years. For continuous covariable evolution, univariate linear regression models were used.
Statistical Analysis
Univariate and multivariable linear regression analyses were used to identify factors associated with higher OQS. The following trial characteristics were investigated: year of publication, tumor site, source of trial funding, journal impact factor (IF), geographic region, positivity of primary outcome, and sample size. The multivariable model included every covariate associated with a P value lower than .10 in the univariate analysis. A high α level of significance was deemed acceptable to reduce the risk of excluding potential independent factors from the multivariate analysis.
It was also hypothesized that manuscripts from the same journal might have OQSs that were more closely correlated to each other than manuscripts from different journals. Therefore, generalized estimating equations were used as a supportive regression analysis with incorporation of an unstructured correlation term for manuscripts from the same journal. Results were similar to those of the linear model without the assumption of correlation. Therefore, for simplicity, only the results of the linear model are reported here. Statistical analyses were performed using SAS version 9.1 (Cary, NC). All statistical tests were two-sided.
Results

Characteristics of Selected RCTs
A total of 357 RCTs met the inclusion criteria and were included in this analysis (Table 3) . From the 659 trials initially screened, 357 primary reports met inclusion criteria ( Figure 1 ). Details of these trials have been reported previously (13) . Overall, 61% of trials were at least partially funded by the pharmaceutical industry (Table 3) 
Rating of Overall Quality Score
The mean 2001 OQS for all items was 13.4 on a 0 to 18 scale [range: 6-18, 95% confidence interval (CI) = 9 to 17], demonstrating that Moreover, the CONSORT diagram was more commonly observed in high-IF journals (P = .015). Among publications that described the blinding process, most were open label trials (76%, n = 111).
The most common description of method of allocation concealment was centralized randomization (95%, n = 172). Among the 104 RCTS with adequate reporting of random allocation, the sequence was generated by the process of dynamic allocation of baseline factors in 72 RCTs. Mean 2010 OQS was 19.3 on a 0 to 27 scale ( Table 2 ). Items that were additions or were redefined in the 2010 CONSORT statement were more likely to be poorly reported. The exception was abstract structure (Table 2) , which was clearly reported in 90% of RCTs.
Factors Associated With Reporting Quality
In univariate analyses, the following trial characteristics were associated with higher 2001 OQS: recent year of publication (P = .005), at least partial funding from the pharmaceutical industry (P = .004), larger sample size (P = .052), high journal IF (P < .001), trials of adjuvant treatment (P = .087), trials with positive results (P = .007), and RCTs conducted outside North America (P = .029) ( Table 4) .
The multivariable regression model subsequently revealed that year of publication (P = .008), journal IF (P = .003), geographic region (P = .003), funding source (P = .079), and treatment type (P = .085) were independent predictors of 2001 OQS. Sample size, tumor type, and positivity of trial results were not associated with higher reporting quality, whereas funding source (P = .079) and treatment type (P = . 
Discussion
To our knowledge, this is the first large-scale study of conformity of oncology randomized clinical trial publications to CONSORT criteria. Poor reporting of RCT findings can result in overestimation of treatment effect and may potentially lead to erroneous conclusions (2, (16) (17) (18) . It is encouraging that this study shows an improvement in the reporting quality of oncology RCTs between 2005 and 2009, which is consistent with smaller previously published reports in various oncology subspecialties (8) (9) (10) 12, 19, 20) . Median OQS rose from 65% to 70% (9.5/15 to 10/15) in previous studies of oncology subspecialties or other medical specialties (10, 14) to 77% (14/18) in this study. More recent publications were more likely to adhere to the CONSORT criteria, possibly reflecting the increased uptake of the CONSORT guidelines by the International Committee of Medical Journal Editors and journal editorial boards since 2001 (21) . A number of other factors were also associated with improved reporting quality, including high IF for the publishing journal. This finding is similar to the results of other studies (8, 10, 14, 22) and may be explained by stricter peer review or higher scrutiny before submission to high-IF journals. Furthermore, rejection of poorly reported RCTs by high-IF journals may explain publications in lower IF journals. Industry funding was another factor associated with improved reporting quality in this study. Although industry funding has been associated with better reporting quality in some reports (8, 14) , others have found industry funding to be associated with publication biases (23) (24) (25) . In this study, complex funding arrangements may not be clearly reported and could have biased the analysis, although the reporting quality of industry funded RCTs appeared to be at least equivalent to that of government or academic trials. Finally, trials from outside of North America and Europe were better reported. Because some trials are international, the geographical origin of the first author may be different from that of the sponsor. However, except for intergroup trials performed on several continents, the sponsor and the first author are frequently from the same geographical regions of the world. Although we observed an overall improvement in RCT reporting over time, some items remained poorly reported. Items pertaining to clinical features such as measures of outcomes, eligibility criteria, intervention, or baseline data (75%, 95%, 90%, and 99%, respectively) were usually better reported than methodological items such as randomization sequence generation, sample size, allocation concealment, blinding, and ITT (29%, 67%, 51%, 41%, and 62% of studies, respectively). This finding may result from a perception that the clinical aspects of RCTs are of greater importance and interest, particularly because many authors of such articles are clinicians. Therefore, paucity of data about the methodological aspects of RCTs may reflect a deliberate de-emphasis, especially when article lengths are limited, rather than shortcomings in trial design or execution (3, 20, (26) (27) (28) . Several authors have demonstrated a strong association between poorly reported trials and poorly designed or conducted trials (20, 27) . Another group found that poorly reported allocation concealment is frequently related to unclear allocation concealment procedure in the trial protocol (3). However, most of these statements were made during the 1980s and 1990s, before development of data and trial design computerization. Nevertheless, adequate reporting of trial methodology is critical to avoid publication biases and to help readers decide whether the study conclusions are valid. Therefore, efforts should be made to improve the reporting of CONSORT items in future publications.
The current study has a number of limitations. Our analysis was limited to published studies, and therefore it is potentially subject to publication bias. Indeed, it is known that some RCTs, especially those with negative results, are never published (24) . In addition, some RCTs may have been poorly designed, or manuscripts may have been so poorly written that they were rejected for publication. Such manuscripts would likely have low OQSs and would lead to a worse overall quality of oncology RCTs. Furthermore, although we report on the adequacy of reporting, as defined by the number of CONSORT-mandated items reported, we are unable to comment on the accuracy of reporting because we were unable to compare the publications to the actual trial protocols (29) . The recent decision of Journal of Clinical Oncology to require access to the full study protocol for the submission of all RCTs might facilitate this type of analysis in the future (30) . Finally, a single investigator rated most publications, which could have introduced subjectivity into the process. Although explanatory notes are provided in the CONSORT statement (31), the requirements for clear reporting of some items, such as allocation concealment, blinding, or settings and locations, are complex. To reduce subjectivity, a data collection template was designed and piloted before its use for data collection in this study. The rating process considered only the blinding of patients and physicians and not those involved in outcome assessment and data analysis. Definition and interpretation of blinding vary considerably among publications (32) . However, blinding of patients and treating physicians is the most important safeguard of methodological quality, even if a full blinding process does not guarantee real blinding (16, 26) . ITT was considered well reported if readers had enough information about the procedure used to determine the analyzed population and if this procedure was consistent with the text. We did not assess whether ITT definition was concordant with standard criteria (17, 33) . The CONSORT statement is a set of recommendations for reporting RCTs and does not dictate how trials should be conducted. In addition, it was too challenging to rate the reporting of qualitative items such as trial limitation, external validity, and general interpretation of the results with reproducibility, and therefore those items were not included in the primary analysis of 2001 OQS.
In previous studies (8, 10, 14, 27) , three key methodological items including ITT, blinding, and allocation concealment reporting were singled out as being associated with increased overall reporting quality (27) and were often analyzed separately from the other CONSORT items (8, 10, 14) . Although these three items are likely associated with improved overall reporting quality, each CONSORT item by itself is also associated with improved overall reporting quality, and there is no differentiation of these three items in the CONSORT statements. Indeed, these three items reflect only the methodological aspect of trials, although it is also important to adequately report clinical aspects. Because it was unclear whether there was sufficient rationale for separating these three items from the remaining items, the primary analysis was based on a single analysis that included all items. In conclusion, our findings show that the reporting quality of oncology RCTs has improved statistically significantly over time and is associated with high-IF journals. However, the fact that some items remain very poorly reported is a concern, given data showing that failures in reporting may conceal important problems in trial design or conduct. Therefore, we recommend that oncology journals require even stricter adherence to the CONSORT guidelines, and manuscript preparation should be conducted in full collaboration among methodologists, statisticians, and clinicians.
